Genmab A/S

Roche affiliate Genentech revealed on July 18 that the US Food and Drug Administration denied a supplemental approval for its bispecific antibody Columvi (glofitamab-gxbm) in relapsed/refractory diffu

Genmab has been boosted by new data for its antibody-drug conjugate, rinatabart sesutecan (Rina-S), but is aiming to move fast to keep ahead of competitor Lilly. The latest Phase I/II trial results fr

Merck & Co.’s initial Phase II/III waveLINE-003 data for zilovertamab vedotin (zilo-V) in diffuse large B-cell lymphoma (DLBCL) at the American Society of Clinical Oncology meeting in Chicago rais

GSK could this week learn whether the European Medicines Agency will recommend pan-EU marketing authorization for Blenrep (belantamab mafodotin), its antibody-drug conjugate that was withdrawn from ma